Cellectar Biosciences (CLRB) Other financing activities (2010 - 2025)
Cellectar Biosciences (CLRB) posted Other financing activities of $7.2 million for Q4 2025, down 58.76% sequentially from $17.6 million in Q3 2024.
Cellectar Biosciences (CLRB) Other financing activities (2010 - 2025) Analysis & Trends
Cellectar Biosciences has reported Other financing activities for 12 years, with the latest figure at $7.2 million in Q4 2025.
- Quarterly Other financing activities changed N/A year-over-year to $7.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $24.8 million (down 59.61% YoY) and the FY2025 annual result came in at $7.2 million, down 88.21% from the prior year.
- Other financing activities fell to $7.2 million in Q4 2025 per CLRB's latest filing, from $17.6 million in the prior quarter.
- Over five years, Other financing activities peaked at $43.8 million in Q1 2024 and troughed at $1.0 in Q2 2024.
- A 4-year average of $8.8 million and a median of $827462.5 in 2021 frame the typical range for Other financing activities.
- The widest YoY moves for Other financing activities: up 1461648800.0% in 2024, down 4937.13% in 2024.
- Over 4 years, Other financing activities stood at $1.2 million in 2021, then tumbled by 63.67% to $441001.0 in 2023, then jumped by 3882.16% to $17.6 million in 2024, then slumped by 58.76% to $7.2 million in 2025.
- According to Business Quant data, Other financing activities over the past three periods registered $7.2 million, $17.6 million, and $1.0 for Q4 2025, Q3 2024, and Q2 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.03 Bn | 131.18 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn |
| 4 | Moderna | 57.93 Bn | 52.80 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.95 Bn | 36.86 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.51 Bn | 28.20 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.00 Bn | 9.60 Bn | 668.28 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - |
| 10 | Cellectar Biosciences | 6.68 Mn | 6.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.24 Mn |
| Dec 31, 2025 | 7.24 Mn |
| Sep 30, 2024 | 17.56 Mn |
| Sep 30, 2024 | 17.56 Mn |
| Jun 30, 2024 | 1.00 |
| Jun 30, 2024 | 1.00 |
| Mar 31, 2024 | 43.85 Mn |
| Mar 31, 2024 | 43.85 Mn |
| Dec 31, 2023 | 441,001.00 |
| Dec 31, 2023 | 441,001.00 |
| Sep 30, 2023 | 348,638.00 |
| Sep 30, 2023 | 348,638.00 |
| Mar 31, 2023 | 3.00 |
| Mar 31, 2023 | 3.00 |
| Mar 31, 2021 | 1.21 Mn |
| Mar 31, 2021 | 1.21 Mn |
| Dec 31, 2020 | 610,798.00 |
| Dec 31, 2020 | 610,798.00 |
| Sep 30, 2020 | 31,683.00 |
| Sep 30, 2020 | 31,683.00 |